BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of $1.12, $1.08 better than the analyst estimate of $0.04. Revenue for the quarter came in at $406.55 million versus the consensus estimate of $150.06 million.

Financial Outlook for 2026
The company maintained its expectation for full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million and for full year 2026 total revenue, including RAPIVAB® (peramivir injection), to be between $635 million and $660 million.

The company also maintained its expectation for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to be between $450 million and $470 million

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.